Paloma Partners’s BioCryst Pharmaceuticals BCRX Stock Holding History

Paloma Partners’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-17,700	Closed	-$51K	–	2146
2019 Q3	$51K	Buy	+17,700	New	+$55.1K	﹤0.01%	1875
2019 Q2	–	Sell	-13,774	Closed	-$112K	–	1729
2019 Q1	$112K	Buy	13,774 +3,376	+32%	+$28.9K	﹤0.01%	1589
2018 Q4	$84K	Buy	+10,398	New	+$80.9K	﹤0.01%	1127
2018 Q3	–	Sell	-30,300	Closed	-$174K	–	1549
2018 Q2	$174K	Buy	+30,300	New	+$167K	﹤0.01%	1492
2017 Q4	–	Sell	-10,328	Closed	-$54K	–	1878
2017 Q3	$54K	Buy	+10,328	New	+$52.9K	﹤0.01%	2046
2015 Q4	–	Sell	-14,482	Closed	-$165K	–	1704
2015 Q3	$165K	Sell	14,482 -33,018	-70%	-$441K	﹤0.01%	1486
2015 Q2	$709K	Buy	+47,500	New	+$540K	0.01%	922
2013 Q3	–	Sell	-229,064	Closed	-$355K	–	925
2013 Q2	$355K	Buy	+229,064	New	+$395K	0.02%	599

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Paloma Partners's BCRX Position: Q4 2019 in Review

Paloma Partners sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2019, closing a stake of 17,700 shares — an estimated $51K sold.

Paloma Partners first reported a position in BCRX in Q2 2013 and held it in 8 quarters. The position peaked at $709K in Q2 2015. 136 funds tracked by Wall St. Rank hold BCRX as of Q4 2019.

Paloma Partners reported no remaining BioCryst Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Paloma Partners sold 17,700 BioCryst Pharmaceuticals shares in Q4 2019, an estimated $51K.
Paloma Partners first reported a position in BioCryst Pharmaceuticals in Q2 2013 and held it in 8 quarters.
Paloma Partners's BioCryst Pharmaceuticals position peaked at $709K in Q2 2015.
136 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2019.

Based on Paloma Partners's 13F filing for Q4 2019, filed 14 Feb 2020.